Mendus
9.325
SEK
-0.78 %
IMMU
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
185 following
-0.78%
-6.75%
+13.87%
+14.84%
+4.31%
-10.85%
-20.03%
-90.69%
-94.46%
-92.95%
mendus.com
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
P/E (adj.) (24e)
-3.78
EV/EBIT (adj.) (24e)
-3.19
P/B (24e)
0.72
Dividend yield-% (24e)
-
Target price
14.00 SEK
Recommendation
Accumulate
Updated
11.11.2024
NASDAQ Stockholm
IMMU
Daily low / high price
9.101 / 9.4
SEK
Market cap
469.6M SEK
Turnover
104.27K SEK
Volume
11K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Siltanen
Analyst
Latest videos
Financial calendar
Annual report
13.02.2025
General meeting
09.05.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Adrianus Van Herk | 35.7 % | 35.7 % |
| Flerie Invest AB | 23.9 % | 23.9 % |
| Fourth Swedish National Pension Fund (AP4) | 9.9 % | 9.9 % |
| Avanza Pension | 2.5 % | 2.5 % |
| Holger Blomstrand Byggnads AB | 1.3 % | 1.3 % |
| Nordnet Pensionsförsäkring | 1.3 % | 1.3 % |
| SEB Funds | 0.7 % | 0.7 % |
| Staffan Wensing | 0.6 % | 0.6 % |
| Erik Manting | 0.6 % | 0.6 % |
| Handelsbanken Fonder | 0.5 % | 0.5 % |
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| growth-% | 150.0 % | -60.0 % | 150.0 % | |||||
| EBITDA | -86.9 | -132.0 | -138.5 | -133.2 | -123.2 | -117.4 | -92.4 | -94.7 |
| EBIT (adj.) | -86.0 | -130.1 | -133.7 | -125.9 | -123.2 | -117.4 | -92.4 | -94.7 |
| EBIT | -86.0 | -130.1 | -133.7 | -125.9 | -123.2 | -117.4 | -92.4 | -94.7 |
| Profit before taxes | -89.2 | -133.4 | -138.8 | -126.9 | -124.4 | -120.4 | -95.4 | -97.7 |
| Net income | -89.2 | -133.4 | -138.8 | -126.9 | -124.4 | -120.4 | -95.4 | -97.7 |
| EPS (adj.) | -10.74 | -13.38 | -13.92 | -3.04 | -2.47 | -2.39 | -1.90 | -1.94 |
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -869,130.0 % | -3,298,775.0 % | -1,385,420.0 % | -1,332,210.0 % | -1,231,930.0 % | -1,174,410.0 % | -924,473.0 % | -946,710.0 % |
| EBIT-% (adj.) | -860,270.0 % | -3,252,500.0 % | -1,336,940.0 % | -1,259,210.0 % | -1,231,930.0 % | -1,174,410.0 % | -924,473.0 % | -946,710.0 % |
| EBIT-% | -860,270.0 % | -3,252,500.0 % | -1,336,940.0 % | -1,259,210.0 % | -1,231,930.0 % | -1,174,410.0 % | -924,473.0 % | -946,710.0 % |
| ROE | -27.2 % | -20.2 % | -23.7 % | -20.8 % | -18.3 % | -20.2 % | -19.6 % | -24.9 % |
| ROI | -25.3 % | -19.4 % | -22.3 % | -20.2 % | -18.1 % | -18.8 % | -15.7 % | -16.1 % |
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (SEK) | 6.82 | 3.95 | 2.22 | 0.52 | 9.33 | 9.33 | 9.33 | 9.33 |
| Shares | 8.3 | 10.0 | 10.0 | 41.8 | 50.4 | 50.4 | 50.4 | 50.4 |
| Market cap | 56.6 | 39.4 | 22.1 | 21.9 | 469.6 | 469.6 | 469.6 | 469.6 |
| Enterprise value | -87.8 | -115.9 | 9.5 | -98.9 | 393.1 | 513.5 | 609.0 | 706.6 |
| EV/S | - | - | 948.4 | - | 39,306.7 | 51,350.8 | 60,895.5 | 70,662.6 |
| EV/EBITDA | 1.0 | 0.9 | - | 0.7 | - | - | - | - |
| EV/EBIT (adj.) | 1.0 | 0.9 | - | 0.8 | - | - | - | - |
| EV/EBIT | 1.0 | 0.9 | - | 0.8 | - | - | - | - |
| P/E (adj.) | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
| P/B | 0.1 | 0.1 | 0.0 | 0.0 | 0.7 | 0.9 | 1.1 | 1.4 |
| P/S | 5,663.0 | 9,837.9 | 2,213.4 | 2,186.5 | 46,960.3 | 46,960.3 | 46,960.3 | 46,960.3 |
| Dividend yield | ||||||||
| Equity ratio | 90.7 % | 91.1 % | 82.9 % | 93.2 % | 92.2 % | 83.5 % | 68.6 % | 53.4 % |
| Gearing ratio | -21.8 % | -23.6 % | -2.5 % | -17.1 % | -11.7 % | 8.2 % | 31.6 % | 69.2 % |
Quarter data
| Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | |||||
| EBITDA | -29.0 | -42.7 | -133.2 | -35.3 | -34.1 | -22.7 | -31.1 | -123.2 | -29.2 |
| EBIT | -25.9 | -42.7 | -125.9 | -35.3 | -34.1 | -22.7 | -31.1 | -123.2 | -29.2 |
| Profit before taxes | -52.2 | -41.2 | -126.9 | -35.6 | -34.4 | -23.0 | -31.4 | -124.4 | -29.2 |
| Net income | -52.2 | -41.2 | -126.9 | -35.6 | -34.4 | -23.0 | -31.4 | -124.4 | -29.2 |
ShowingAll content types
Mendus Q3'24: Building basis for a pivotal trial
Mendus, Audiocast with teleconference, Q3'24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Mendus Announces Nomination Committee for the 2025 Annual General Meeting
Mendus AB Interim Report January – September 2024
Mendus to present preclinical data supporting the combination potential of ilixadencel with the immune checkpoint inhibitor avelumab at SITC 2024
Mendus to present multiple abstracts at ASH 2024, including survival update of ADVANCE II trial with lead program vididencel in AML
Mendus Q3’24 preview: New ilixadencel trial preparations underway
Invitation to third quarter financial report and business update
Mendus announces industry conference participation in October-November
Probabilities of success in drug development
Clinical phases of drug development
Invitation to Mendus in-person investor events with management
Mendus to participate in upcoming industry conferences in September
Mendus Q2'24: Ilixadencel to return to the clinical arena
Redeye: Mendus Q2 2024 - Catalysts are coming closer, solid funding position
Mendus Q2´24: The CADENCE trial has started
